A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer

Ioannis Hatzaras, Ana L. Gleisner, Carlo Pulitano, Charbel Sandroussi, Kenzo Hirose, Omar Hyder, Christopher L. Wolfgang, Luca Aldrighetti, Michael Crawford, Michael A. Choti, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

Objectives: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM. Methods: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and 2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and outcome data were collected and analysed. Results: Mean patient age was 62.4 years and most patients (67.4%) were male. The mean tumour size of the primary RCC was 6.9 cm and most tumours (72.1%) were designated as clear cell carcinoma. Nine patients (20.9%) presented with synchronous LM. Among the patients with metachronous disease, the median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1-189.3 months). The mean size of the RCC LM was 4.0 cm and most patients (55.8%) had a solitary metastasis. Most patients (86.0%) underwent a minor resection (up to three segments). Final pathology showed margin status to be negative (R0) in 95.3% of patients. Postoperative morbidity was 23.3% and there was one perioperative death. A total of 69.8% of patients received perioperative chemotherapy. Overall 3-year survival was 62.1%. Three-year recurrence-free survival was 27.3% and the median length of recurrence-free survival was 15.5 months. Conclusions: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and near-zero mortality. Although recurrence occurs in up to 50% of patients, resection can be associated with long-term survival in a well-selected subset of patients.

Original languageEnglish
Pages (from-to)532-538
Number of pages7
JournalHPB
Volume14
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Renal Cell Carcinoma
Liver
Neoplasm Metastasis
Survival
Recurrence
Morbidity
Carcinoma
Neoplasms
Databases
Pathology
Safety
Drug Therapy
Mortality

Keywords

  • Hepatectomy
  • Liver metastasis
  • Metastasectomy
  • Outcomes
  • Renal cell carcinoma
  • Surgery

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Hatzaras, I., Gleisner, A. L., Pulitano, C., Sandroussi, C., Hirose, K., Hyder, O., ... Pawlik, T. M. (2012). A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB, 14(8), 532-538. https://doi.org/10.1111/j.1477-2574.2012.00495.x

A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. / Hatzaras, Ioannis; Gleisner, Ana L.; Pulitano, Carlo; Sandroussi, Charbel; Hirose, Kenzo; Hyder, Omar; Wolfgang, Christopher L.; Aldrighetti, Luca; Crawford, Michael; Choti, Michael A.; Pawlik, Timothy M.

In: HPB, Vol. 14, No. 8, 08.2012, p. 532-538.

Research output: Contribution to journalArticle

Hatzaras, I, Gleisner, AL, Pulitano, C, Sandroussi, C, Hirose, K, Hyder, O, Wolfgang, CL, Aldrighetti, L, Crawford, M, Choti, MA & Pawlik, TM 2012, 'A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer', HPB, vol. 14, no. 8, pp. 532-538. https://doi.org/10.1111/j.1477-2574.2012.00495.x
Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O et al. A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB. 2012 Aug;14(8):532-538. https://doi.org/10.1111/j.1477-2574.2012.00495.x
Hatzaras, Ioannis ; Gleisner, Ana L. ; Pulitano, Carlo ; Sandroussi, Charbel ; Hirose, Kenzo ; Hyder, Omar ; Wolfgang, Christopher L. ; Aldrighetti, Luca ; Crawford, Michael ; Choti, Michael A. ; Pawlik, Timothy M. / A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. In: HPB. 2012 ; Vol. 14, No. 8. pp. 532-538.
@article{5b2d2a7ca13e4666a91104386d22f6ea,
title = "A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer",
abstract = "Objectives: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM. Methods: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and 2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and outcome data were collected and analysed. Results: Mean patient age was 62.4 years and most patients (67.4{\%}) were male. The mean tumour size of the primary RCC was 6.9 cm and most tumours (72.1{\%}) were designated as clear cell carcinoma. Nine patients (20.9{\%}) presented with synchronous LM. Among the patients with metachronous disease, the median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1-189.3 months). The mean size of the RCC LM was 4.0 cm and most patients (55.8{\%}) had a solitary metastasis. Most patients (86.0{\%}) underwent a minor resection (up to three segments). Final pathology showed margin status to be negative (R0) in 95.3{\%} of patients. Postoperative morbidity was 23.3{\%} and there was one perioperative death. A total of 69.8{\%} of patients received perioperative chemotherapy. Overall 3-year survival was 62.1{\%}. Three-year recurrence-free survival was 27.3{\%} and the median length of recurrence-free survival was 15.5 months. Conclusions: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and near-zero mortality. Although recurrence occurs in up to 50{\%} of patients, resection can be associated with long-term survival in a well-selected subset of patients.",
keywords = "Hepatectomy, Liver metastasis, Metastasectomy, Outcomes, Renal cell carcinoma, Surgery",
author = "Ioannis Hatzaras and Gleisner, {Ana L.} and Carlo Pulitano and Charbel Sandroussi and Kenzo Hirose and Omar Hyder and Wolfgang, {Christopher L.} and Luca Aldrighetti and Michael Crawford and Choti, {Michael A.} and Pawlik, {Timothy M.}",
year = "2012",
month = "8",
doi = "10.1111/j.1477-2574.2012.00495.x",
language = "English",
volume = "14",
pages = "532--538",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer

AU - Hatzaras, Ioannis

AU - Gleisner, Ana L.

AU - Pulitano, Carlo

AU - Sandroussi, Charbel

AU - Hirose, Kenzo

AU - Hyder, Omar

AU - Wolfgang, Christopher L.

AU - Aldrighetti, Luca

AU - Crawford, Michael

AU - Choti, Michael A.

AU - Pawlik, Timothy M.

PY - 2012/8

Y1 - 2012/8

N2 - Objectives: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM. Methods: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and 2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and outcome data were collected and analysed. Results: Mean patient age was 62.4 years and most patients (67.4%) were male. The mean tumour size of the primary RCC was 6.9 cm and most tumours (72.1%) were designated as clear cell carcinoma. Nine patients (20.9%) presented with synchronous LM. Among the patients with metachronous disease, the median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1-189.3 months). The mean size of the RCC LM was 4.0 cm and most patients (55.8%) had a solitary metastasis. Most patients (86.0%) underwent a minor resection (up to three segments). Final pathology showed margin status to be negative (R0) in 95.3% of patients. Postoperative morbidity was 23.3% and there was one perioperative death. A total of 69.8% of patients received perioperative chemotherapy. Overall 3-year survival was 62.1%. Three-year recurrence-free survival was 27.3% and the median length of recurrence-free survival was 15.5 months. Conclusions: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and near-zero mortality. Although recurrence occurs in up to 50% of patients, resection can be associated with long-term survival in a well-selected subset of patients.

AB - Objectives: Management of liver metastasis (LM) from a non-colorectal, non-neuroendocrine primary carcinoma remains controversial. Few data exist on the management of hepatic metastasis from primary renal cell carcinoma (RCC). This study sought to determine the safety and efficacy of surgery for RCC LM. Methods: A total of 43 patients who underwent surgery for RCC hepatic metastasis between 1994 and 2011 were identified in a multi-institution hepatobiliary database. Clinicopathologic, operative and outcome data were collected and analysed. Results: Mean patient age was 62.4 years and most patients (67.4%) were male. The mean tumour size of the primary RCC was 6.9 cm and most tumours (72.1%) were designated as clear cell carcinoma. Nine patients (20.9%) presented with synchronous LM. Among the patients with metachronous disease, the median time from diagnosis of the primary RCC to treatment of LM was 17.2 months (range: 2.1-189.3 months). The mean size of the RCC LM was 4.0 cm and most patients (55.8%) had a solitary metastasis. Most patients (86.0%) underwent a minor resection (up to three segments). Final pathology showed margin status to be negative (R0) in 95.3% of patients. Postoperative morbidity was 23.3% and there was one perioperative death. A total of 69.8% of patients received perioperative chemotherapy. Overall 3-year survival was 62.1%. Three-year recurrence-free survival was 27.3% and the median length of recurrence-free survival was 15.5 months. Conclusions: Resection of RCC hepatic metastasis is safe and is associated with low morbidity and near-zero mortality. Although recurrence occurs in up to 50% of patients, resection can be associated with long-term survival in a well-selected subset of patients.

KW - Hepatectomy

KW - Liver metastasis

KW - Metastasectomy

KW - Outcomes

KW - Renal cell carcinoma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84863722901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863722901&partnerID=8YFLogxK

U2 - 10.1111/j.1477-2574.2012.00495.x

DO - 10.1111/j.1477-2574.2012.00495.x

M3 - Article

C2 - 22762401

AN - SCOPUS:84863722901

VL - 14

SP - 532

EP - 538

JO - HPB

JF - HPB

SN - 1365-182X

IS - 8

ER -